Publication
Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient
| datacite.subject.fos | Ciências Médicas | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Cardoso, Margarida | |
| dc.contributor.author | Vasconcelos, Joana | |
| dc.contributor.author | Baptista, Teresa | |
| dc.contributor.author | Diogo, Isabel | |
| dc.contributor.author | Gonçalves, Fátima | |
| dc.contributor.author | Mansinho, Kamal | |
| dc.contributor.author | Gomes, Perpétua | |
| dc.date.accessioned | 2025-09-24T13:55:59Z | |
| dc.date.available | 2025-09-24T13:55:59Z | |
| dc.date.issued | 2021-10 | |
| dc.description.abstract | Background: The current standard of care is to start antiretroviral therapy in all patients diagnosed with HIV-1, as for HIV-2 current DHHS guideline suggests ART for HIV-2 as soon as diagnosis is established, although this practice is not universal, for instance, in Portugal there are specific criteria to start treatment. Case presentation: We present a case of a man, chronically infected with HIV-1, HIV-2 and hepatitis B virus who developed resistance to HIV-2 while maintaining HIV-1 under control. 6 years after starting antiretroviral therapy he had his first virologic failure. We performed HIV-2 resistance tests that revealed high-grade resistance to all nucleoside reverse-transcriptase inhibitors except tenofovir and to all protease inhibitors except darunavir. After a decade of permanent poor adherence to therapy he developed resistance to both tenofovir and darunavir. We put together a new regiment with tenofovir alafenamide + emtricitabine + dolutegravir + maraviroc and nowadays he is with undetectable HIV-1 and HIV-2 viral loads. Conclusions: This shows the importance of having access to HIV-2 viral load determination and HIV-2 resistance testing. | eng |
| dc.identifier.citation | Cardoso, M., Vasconcelos, J., Baptista, T. et al. Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient. AIDS Res Ther 18, 69 (2021). https://doi.org/10.1186/s12981-021-00394-4 | |
| dc.identifier.doi | 10.1186/s12981-021-00394-4 | |
| dc.identifier.issn | 1742-6405 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/58821 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Springer Nature | |
| dc.relation.hasversion | https://doi.org/10.1186/s12981-021-00394-4 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | HIV-2 | |
| dc.subject | HIV-1 | |
| dc.subject | Resistance | |
| dc.subject | Mutation | |
| dc.subject | Coinfection | |
| dc.subject | Antiretroviral therapy | |
| dc.title | Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.startPage | 69 | |
| oaire.citation.title | AIDS Research and Therapy | |
| oaire.citation.volume | 18 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |